Search Results 1851-1860 of 4061 for Solid
... Solid Tumors (RECIST) criteria; Ability to understand and the willingness to sign a written informed consent document; Histological or cytologically confirmed ...
... cancer (e.g., basal cell or squamous cell carcinoma). - Participant has a solid organ transplant and/or is currently receiving treatment with therapy for ...
A Pilot Study to Evaluate the Molecular and Biological Phenotype of Peripheral Immune Cells in Solid Tumor Patients. Rochester, Minn. The purpose of this ...
... solid tumors. It is necessary that ctDNA test results are linked to clinical outcomes in order to demonstrate clinical validity for recurrence detection and ...
We hope that regenerative sciences will discover and perfect ways to expand this treatment approach to solid cancers, as well," says Dr. Terzic ...
Other completely resected stage 1 solid tumor with low risk for recurrence. Treatment with any prior gene therapy product. Subjects who have received ...
Phase 2 only: To assess preliminary antitumor activity by overall response rate (ORR) as measured by Response Evaluation Criteria in Solid Tumors (RECIST) v1.
Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria is required except for subjects with bone only disease. All prior ...
... solid tumor patients. A Study To Evaluate Oncologic Outcomes And Quality Of Life In Sinonasal Cancer Patients. Rochester, Minn. This is a multi-site study ...
... Solid Tumors version 1.1 (RECIST 1.1) after initial treatment. A Study Evaluating The Safety, Efficacy, And Pharmacokinetics Of Mosunetuzumab And A Combined ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Hurry to 3X your gift’s impact on cancer research and care!